Nathan Starr

669 total citations
7 papers, 448 citations indexed

About

Nathan Starr is a scholar working on Infectious Diseases, Hematology and Molecular Biology. According to data from OpenAlex, Nathan Starr has authored 7 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Infectious Diseases, 3 papers in Hematology and 2 papers in Molecular Biology. Recurrent topics in Nathan Starr's work include COVID-19 Clinical Research Studies (3 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Parkinson's Disease Mechanisms and Treatments (2 papers). Nathan Starr is often cited by papers focused on COVID-19 Clinical Research Studies (3 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Parkinson's Disease Mechanisms and Treatments (2 papers). Nathan Starr collaborates with scholars based in United States. Nathan Starr's co-authors include Ithan D. Peltan, Whitney R. Buckel, Samuel M. Brown, Brandon Webb, Rajendu Srivastava, Dave Morris, Bradley D. Hunter, Edward Stenehjem, Paul N. Jensen and Gregory L. Snow and has published in prestigious journals such as JAMA Neurology, Alzheimer s & Dementia and Annals of the American Thoracic Society.

In The Last Decade

Nathan Starr

7 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nathan Starr United States 5 226 183 92 67 61 7 448
Anannit Visudtibhan Thailand 16 86 0.4× 60 0.3× 69 0.8× 48 0.7× 54 0.9× 62 616
Shouping Gong China 10 74 0.3× 135 0.7× 100 1.1× 11 0.2× 33 0.5× 38 403
Katalin Jakab Hungary 10 92 0.4× 36 0.2× 112 1.2× 36 0.5× 20 0.3× 33 409
Maya Thomas India 11 62 0.3× 39 0.2× 94 1.0× 51 0.8× 14 0.2× 54 382
AJ Ferreira Brazil 4 55 0.2× 145 0.8× 107 1.2× 24 0.4× 9 0.1× 4 458
Siddharth Krishnan United Kingdom 9 75 0.3× 99 0.5× 92 1.0× 15 0.2× 7 0.1× 13 489
Dongmei Zhang China 8 133 0.6× 62 0.3× 167 1.8× 14 0.2× 11 0.2× 16 355
Stefan D. Jevtic Canada 9 35 0.2× 69 0.4× 122 1.3× 18 0.3× 57 0.9× 17 409
Simona Signorini Italy 13 106 0.5× 41 0.2× 86 0.9× 32 0.5× 22 0.4× 24 504
V. Sazdovitch France 16 152 0.7× 49 0.3× 243 2.6× 39 0.6× 10 0.2× 28 607

Countries citing papers authored by Nathan Starr

Since Specialization
Citations

This map shows the geographic impact of Nathan Starr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Starr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Starr more than expected).

Fields of papers citing papers by Nathan Starr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Starr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Starr. The network helps show where Nathan Starr may publish in the future.

Co-authorship network of co-authors of Nathan Starr

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Starr. A scholar is included among the top collaborators of Nathan Starr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Starr. Nathan Starr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Starr, Nathan, et al.. (2022). Intermountain Healthcare's Hospital-Level Care at Home Program. Quality Management in Health Care. 31(4). 281–283. 1 indexed citations
2.
Brown, Samuel M., Ithan D. Peltan, Lindsay Leither, et al.. (2020). Hydroxychloroquine versus Azithromycin for Hospitalized Patients with COVID-19. Results of a Randomized, Active Comparator Trial. Annals of the American Thoracic Society. 18(4). 590–597. 20 indexed citations
3.
Brown, Samuel M., Ithan D. Peltan, Brandon Webb, et al.. (2020). Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS). Protocol for a Pragmatic, Open-Label, Active Comparator Trial. Annals of the American Thoracic Society. 17(8). 1008–1015. 21 indexed citations
4.
Webb, Brandon, Ithan D. Peltan, Paul N. Jensen, et al.. (2020). Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. The Lancet Rheumatology. 2(12). e754–e763. 214 indexed citations
5.
Turner, Raymond Scott, Michaeline Hebron, Abigail Lawler, et al.. (2020). Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease: A phase 2, double‐blind, randomized, placebo‐controlled trial. Alzheimer s & Dementia. 16(S9). 1 indexed citations
6.
Pagán, Fernando, Michaeline Hebron, Barbara Wilmarth, et al.. (2019). Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease. Pharmacology Research & Perspectives. 7(2). e00470–e00470. 73 indexed citations
7.
Pagán, Fernando, Michaeline Hebron, Barbara Wilmarth, et al.. (2019). Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease. JAMA Neurology. 77(3). 309–309. 118 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026